Momenta

Investor Relations

NASDAQ: MNTA
Price
11.73
Change
- 0.05
Day High
12.00
Day Low
11.70
Volume
267,900
1:00 PM ET on Nov 28, 2014
Stock price graph

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

In July 2010, the Momenta’s lead product (developed in collaboration with Sandoz) was approved as the first generic version of Lovenox® (Enoxaparin Sodium Injection).  The company’s development pipeline includes a generic version of Copaxone® (glatiramer acetate), also in collaboration with Sandoz, biosimilars in collaboration with Baxter.    necuparanib (formerly M402), a novel oncology drug candidate currently undergoing testing in early phase human clinical trials, and a portfolio of novel autoimmune drug candidates.

View Annual Report and Proxy Material

View all »   RSSRecent Releases

Nov 24, 2014
Momenta Pharmaceuticals to Webcast Presentation at 2014 Deutsche Bank BioFEST

Nov 6, 2014
Momenta Pharmaceuticals to Webcast Presentation at Three Upcoming Investor Conferences

Nov 5, 2014
Momenta Pharmaceuticals Reports Third Quarter 2014 Financial Results

View all »Events & Presentations

Dec 1, 2014 at 1:40 PM ET
The 2014 Deutsche Bank BioFEST

Last Revised 6/12/2012